November 2024 Digital Pathology Roundup

Dec 31, 2024

This roundup delves into recent advancements in digital pathology, showcasing significant customer expansions like Ibex Medical Analytics' ventures in breast and prostate diagnostics. Exciting partnerships are highlighted, including Lunit Oncology's collaboration with AstraZeneca to enhance AI tools for lung cancer assessment. The discussion also covers the evolving landscape of the industry, emphasizing the integration of genomics with digital pathology and addressing workflow challenges. The outlook for 2025 remains hopeful amidst technological advancements and strategic alliances.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

INSIGHT

Genomics and Digital Pathology Convergence

OptraSCAN's partnership with Molbio Diagnostics signals a growing convergence between genomics and digital pathology vendors.
This reflects the increasing integration of these disciplines in laboratory settings, particularly regarding AI algorithms and genomic biomarkers.

ADVICE

IMS Integrations and Market Consolidation

Third-party integrations on IMS platforms are increasing, as seen with Owkin on Proscia's Concentriq and PathAI incorporating multiple vendors.
Evaluate the long-term impact of these partnerships and consider the potential for market consolidation before extensive integration.

ANECDOTE

Ibex Customer Expansions

Ibex Medical Analytics reported expansions with Alverno Laboratories and Institut Curie, demonstrating real-world value and adoption of their AI solutions.
This counters the industry trend of announcements without clear evidence of actual implementation or customer benefit.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

Happy Holidays Everyone! Here is the Digital Pathology Round-Up covering events in November with Imogen Fitt of Signify Research. There will be no December roundup but rather an assessment of the state of the industry and Predictions for 2025 coming in January. Customer Expansions: Ibex Medical Analytics announced significant expansions with existing customers. Alverno Laboratories, operating in Illinois and Indiana, launched Ibex’s AI-based breast cancer diagnostic platform, building on its earlier adoption of prostate diagnostics. A gastric platform is also in development. Meanwhile, France’s Institut Curie deployed Ibex’s prostate solution, with further expansions planned. These updates highlight the slow but steady adoption of AI in pathology, reinforcing its value despite lengthy validation processes. Partnerships: OptraSCAN secured $30M in Series B funding, led by Molbio Diagnostics, to accelerate R&D, expand global sales, and enhance AI pathology tools. Partnerships between genomics and digital pathology firms are expected to deepen as AI solutions advance. Lunit Oncology also announced a collaboration with AstraZeneca to develop AI-powered digital pathology tools for assessing non-small cell lung cancer (NSCLC) risks. Using Lunit’s SCOPE Genotype Predictor, this partnership focuses on identifying key mutations, marking Lunit’s first direct deal with a global pharmaceutical company. Third-Party Integrations: Owkin launched its MSIntuit CRC v2 test for colorectal cancer screening on Proscia’s Concentriq platform and joined the Proscia Ready alliance. The focus now shifts to the implementation of these integrations, whether as pop-ups or embedded tools, and the timeline for deployment. PathAI also announced the integration of tools from Deep Bio, DoMore Diagnostics, Paige, and Visiopharm into its AISight platform. With many IMS platforms adding third-party AI tools, differentiation strategies for vendors in an increasingly crowded market remain a key question